Stockscreener 앱 받기
11.56
1.85%
0.21
전일 마감가:
$11.35
열려 있는:
$11.31
하루 거래량:
2.37M
Relative Volume:
2.26
시가총액:
$1.23B
수익:
-
순이익/손실:
$-249.31M
주가수익비율:
-3.4924
EPS:
-3.31
순현금흐름:
$-209.70M
1주 성능:
-3.83%
1개월 성능:
-11.35%
6개월 성능:
-44.56%
1년 성능:
-58.57%
1일 변동 폭
$11.15
$11.79
1주일 범위
$11.15
$12.87
52주 변동 폭
$11.15
$32.52
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
명칭
Rocket Pharmaceuticals Inc
전화
646-440-9100
주소
350 FIFTH AVENUE, NEW YORK, NY
RCKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
11.56 | 1.23B | 0 | -249.31M | -209.70M | -2.87 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-18 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 개시 | Morgan Stanley | Overweight |
| 2022-11-08 | 개시 | Canaccord Genuity | Buy |
| 2022-11-01 | 개시 | BTIG Research | Buy |
| 2022-07-08 | 개시 | Raymond James | Outperform |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2021-02-18 | 개시 | Needham | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 개시 | JP Morgan | Overweight |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2019-11-06 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-26 | 개시 | Piper Jaffray | Overweight |
| 2019-04-23 | 개시 | Robert W. Baird | Outperform |
| 2019-03-15 | 개시 | BofA/Merrill | Buy |
| 2019-02-05 | 개시 | Oppenheimer | Outperform |
| 2018-09-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-10 | 개시 | William Blair | Outperform |
모두보기
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy' - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 1-Year LowWhat's Next? - MarketBeat
State Street Corp Buys 322,156 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Franklin Resources Inc. Cuts Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
State Street Corp Has $57.29 Million Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap UpWhat's Next? - MarketBeat
Jefferies Financial Group Initiates Coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) - MarketBeat
Head-To-Head Review: InMed Pharmaceuticals (NASDAQ:INM) & Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
RTW INVESTMENTS, LP Increases Stake in Rocket Pharmaceuticals Inc - GuruFocus.com
(RCKT) Trading Report - Stock Traders Daily
Synovus Financial Corp Decreases Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Leerink Partnrs Has Positive Outlook of RCKT FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for RCKT Issued By Leerink Partnrs - Defense World
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com Australia
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals (NASDAQ:RCKT) Hits New 1-Year LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals completes $178.1 million offering - Investing.com India
Rocket Pharmaceuticals completes $178.1 million offering By Investing.com - Investing.com Australia
RSI Alert: Rocket Pharmaceuticals (RCKT) Now Oversold - Nasdaq
RCKT Stock Hits 52-Week Low at $12.62 Amid Market Challenges - Investing.com India
RCKT Stock Hits 52-Week Low at $12.62 Amid Market Challenges By Investing.com - Investing.com South Africa
Fmr LLC Lowers Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals sets $12.50 share price for offering By Investing.com - Investing.com South Africa
Watkins Advises on Rocket Pharmaceuticals’ Upsized Public Offering of Common Stock - Latham & Watkins LLP
Rocket Pharmaceuticals sets $12.50 share price for offering - Investing.com India
Rocket Pharmaceuticals Secures $165M Through Upsized Public Stock Offering at $12.50 Per Share - StockTitan
Rocket Pharmaceuticals plans $150 million stock offering By Investing.com - Investing.com Canada
Point72 Asset Management L.P. Acquires Shares of 48,096 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals plans $150 million stock offering - Investing.com India
Rocket Pharmaceuticals Plans $150 Million Public Offering of Common Shares - Marketscreener.com
Rocket Pharmaceuticals Launches $150M Public Offering to Advance Genetic Therapy Pipeline - StockTitan
Frazier Life Sciences Management L.P. Sells 75,600 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Wellington Management Group LLP Acquires 2,086,424 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Janus Henderson Group PLC Has $35.06 Million Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
(RCKT) Investment Report - Stock Traders Daily
44,700 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Purchased by Erste Asset Management GmbH - MarketBeat
Walleye Capital LLC Buys New Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rocket Pharmaceuticals Offers Huge Potential as Price Targets Exceed 300% Growth - TheStreet
Bamco Inc. NY Sells 94,990 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain (RCKT) - Seeking Alpha
RCKT (Rocket Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Nov. 30, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Cash From Other Investing Act - GuruFocus.com
RCKT (Rocket Pharmaceuticals) PE Ratio without NRI : At Loss (As of Nov. 29, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Cash, Cash Equivalents, Marke - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Price-to-Free-Cash-Flow : N/A (As of Nov. 28, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) 50-Day SMA : $16.76 (As of Nov. 28, 2024) - GuruFocus.com
Acuta Capital Partners LLC Sells 60,370 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
3 Small-Cap Stocks That Are Ready to Rocket Higher - sharewise
Fiverr International Ltd (FVRR-N) QuotePress Release - The Globe and Mail
Rocket Pharmaceuticals Inc (RCKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rocket Pharmaceuticals Inc 주식 (RCKT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Patel Kinnari | See Remarks |
Nov 21 '24 |
Sale |
13.05 |
4,588 |
59,892 |
392,395 |
| Shah Gaurav | CEO |
Nov 21 '24 |
Sale |
13.05 |
11,091 |
144,782 |
707,328 |
| Wilson Martin | General Counsel |
Nov 21 '24 |
Sale |
13.05 |
1,175 |
15,338 |
63,560 |
2.88%
2.65%
자본화:
|
볼륨(24시간):